A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM
J Kothari, M Foley, KS Peggs, S Mackenzie… - Bone Marrow …, 2016 - nature.com
Consolidation of responses to salvage chemo-radiotherapy regimens with high-dose
therapy and autologous stem cell transplantation (ASCT) is a standard treatment strategy for …
therapy and autologous stem cell transplantation (ASCT) is a standard treatment strategy for …
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
Abstract High-dose melphalan (MEL200) followed by autologous stem cell transplantation
(ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces …
(ASCT) remains a standard of care for multiple myeloma (MM). Bendamustine induces …
Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: A review of clinical trial data
A Palumbo, M Offidani, F Patriarca… - Leukemia & …, 2015 - Taylor & Francis
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal growth
and/or dysregulation of plasma cells leading to the build-up of malignant plasma cells in the …
and/or dysregulation of plasma cells leading to the build-up of malignant plasma cells in the …
[HTML][HTML] Toxicity of Bendamustine Therapy
S Liewer - 2021 - theoncologypharmacist.com
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of
patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients …
patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients …
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for …
I Sakellari, D Mallouri, I Batsis, C Apostolou… - Leukemia & …, 2015 - Taylor & Francis
Optimal conditioning remains a challenge in lymphomas. We designed a regimen consisting
of Busulfex, etoposide and melphalan (BuEM). We retrospectively analyzed the outcome of …
of Busulfex, etoposide and melphalan (BuEM). We retrospectively analyzed the outcome of …
Successful mobilization of peripheral blood stem cells after intensive bendamustine pre-treatment in patients with multiple myeloma
W Pönisch, J Wiesler, S Leiblein, E Edel, HK Al-Ali… - 2010 - ashpublications.org
Abstract Abstract 4439 Introduction The alkylating agent bendamustine has structural
similarities to both alkylating agents and purine analogs, and is effective in the treatment of …
similarities to both alkylating agents and purine analogs, and is effective in the treatment of …
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review
G Damaj, J Cornillon, K Bouabdallah… - Bone Marrow …, 2017 - nature.com
High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation
(auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin …
(auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin …
Severe mucositis with bendamustine etoposide ara-C and melphalan (Be-EAM) as conditioning regimen in non-Hodgkin lymphoma (NHL) patients undergoing …
S Nathan, AM Jimenez, AD Moreno… - Biology of Blood and …, 2015 - tctjournal.org
Methods Data from 22 consecutive patients (pts), undergoing AutoSCT using the Be-EAM
[Bendamustine200mg/m2 daily D-7,-6, Etoposide 200mg/m2 daily D-5 to-2, Ara-C …
[Bendamustine200mg/m2 daily D-7,-6, Etoposide 200mg/m2 daily D-5 to-2, Ara-C …
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation
H Huang, L Zhang, Y Jiang, S Liu, Z Jin, J Chen… - Annals of …, 2019 - Springer
The aim of this study is to determine whether the modified BuCy (semustine, cytarabine,
busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an …
busulfan, and cyclophosphamide, mBuCy) conditioning regimen can be safely used as an …
[HTML][HTML] Phase 1, open-label, randomized, bioequivalence study of 2 bendamustine hydrochloride formulations; a ready-to-dilute low-volume, rapid infusion solution …
WJ Edenfield, B Mattar, SP Anthony, P Mutch… - Blood, 2015 - Elsevier
Abstract Introduction: This phase 1, open-label, randomized, crossover study assessed the
bioequivalence (BE) and safety of an investigational, ready-to-dilute, rapid infusion, low …
bioequivalence (BE) and safety of an investigational, ready-to-dilute, rapid infusion, low …